STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #369 by analyst upside · 2026-06-27
SGMT
Sagimet Biosciences Inc.
Healthcare · Market Cap $436M · P/E 0x
ANALYST PRICE TARGET
+271.1%
implied upside to consensus target
Current Price $7.06
Consensus Target $26.2
Bull Target $49.0
Bear Target $8.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
8
Hold
1
Sell
0
52-Week Low $4.5
52-Week High $11.41
YTD Return +17.9%
FUNDAMENTALS
Market Cap $436M
P/E Ratio (TTM) N/A
Forward P/E -5.4x
EPS (TTM) $-1.35
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.5
52-Week High $11.41
Current Price $7.06
Bear Target $8.0
Bull Target $49.0
● Now $7.06 ● Target $26.2
TRADING DATA
Avg Volume 1.6M
YTD Return +17.9%
Analyst Count 10
Consensus Buy
Upside to Target +271.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Sagimet Biosciences Inc. (SGMT) is currently trading at $7.06 with a Wall Street consensus price target of $26.2, implying potential upside of 271.1% over the next 12 months. 10 analysts currently cover SGMT, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $49.0, while the most cautious has a target of $8.0.

SGMT operates in the Healthcare sector with a market capitalisation of $436M. The stock is up 17.9% year-to-date and is currently trading near the lower end of its 52-week range of $4.5 – $11.41.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SGMT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-19 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-05-04 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-04-29 62% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-11 31% win rate (48 calls)
Guggenheim ● Initiated
Buy 2026-02-03 62% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-02-03 31% win rate (48 calls)
Barclays ● Initiated
Equal-Weight 2026-01-28 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2025-11-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →